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Purpose: To compare the efficacy and safety of topical mitomycin-C (MMC) drops 
with that of subconjunctival 5-fluorouracil (5-FU) injections for management of early 
bleb failure after trabeculectomy or combined phacoemulsification and trabeculectomy 
with posterior chamber intraocular lens implantation (PT+PCIOL).
Methods: In a randomized comparative study, 37 eyes of 37 patients with impending 
early bleb failure received MMC 0.02% eye drops for 2 or 4 weeks (19 eyes) or 
subconjunctival 5-FU injections, 5 mg per dose (18 eyes). Complete success was 
defined as 5 < IOP ≤ 18 mmHg without medications. 
Results: Baseline characteristics were comparable between the study groups. However, 
there were more cases of combined PT+PCIOL in the MMC group [11 (57.9%) eyes 
versus 3 (16.7%) eyes, P = 0.017]. Mean preoperative IOP was 20.5±8.85 mmHg in 
the MMC group and 25.82±11.35 mmHg in the 5-FU group (P = 0.129), which was 
decreased to 13.2±6.1 and 10.6±4.8 mmHg respectively after 12 months (P = 0.159). 
There was no significant difference between the study groups in terms of bleb extent 
(P = 0.170), height (P = 0.178) or vascularity (P = 0.366). At the end of the study, 
complete success was achieved in 13 eyes (68.4%) in the MMC group and 14 eyes 
(77.8%) in the 5-FU group (P = 0.714). The survival of success at 8 months (median 
follow-up) was 89.5% and 86.5% in the MMC and 5-FU groups respectively; the number 
of glaucoma medications (P = 0.707) and best-corrected visual acuity (P = 0.550) were 
also comparable. Complication rates were similar in the study groups (P = 0.140).
Conclusion: Topical MMC 0.02% has comparable safety and efficacy to subconjunctival 
5-FU injections for management of early bleb failure. Topical MMC 0.02% drops are 
more convenient and can be initiated first, while 5-FU injections may be reserved 
for eyes with an insufficient response to topical MMC.
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INTRODuCTION
Despite the adoption of several surgical 
procedures since the introduction of 
trabeculectomy in 1961, it remains the most 
common glaucoma operation.1 In this procedure, MMC vs 5-FU for Bleb Failure; Pakravan et al
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after dissecting a partial thickness scleral flap, a 
fistula is created between the anterior chamber 
and the subconjunctival space, and a bleb is 
formed under the conjunctiva and Tenon’s 
capsule providing aqueous filtration outside the 
globe.2 Gentle intraoperative tissue handling 
and the use of steroids and anti-fibrotic agents 
have been suggested to maintain the patency of 
this conduit; however, this goal is not always 
attained and postoperative inflammation and 
scar formation may lead to early bleb failure 
during the first few months after surgery.2,3 
Increased vascularity and reduction in bleb 
height and area, with or without an increase in 
intraocular pressure (IOP), constitute the early 
signs of bleb failure. Prompt measures are to 
be taken before permanent adhesions develop 
between the conjunctiva and episclera. The use 
of frequent topical or systemic corticosteroids, 
ocular massage, and the removal of releasable 
sutures or laser suture lysis are initial measures 
for management of this situation. Persistent 
bleb vascularization may be a poor prognostic 
sign for bleb survival and requires prompt 
intervention.1,4 
Adjunctive antimetabolites are used 
postoperatively for further reduction of 
subconjunctival fibrosis, which is especially 
important in eyes at high risk of failure. 
Postoperative subconjunctival injections of 
5-fluorouracil (5-FU) can retard bleb fibrosis 
and enhance filtration, but are inconvenient 
for both the patient and surgeon, furthermore 
they entail complications such as corneal and 
conjunctival epithelial toxicity, corneal ulcers, 
and inadvertent intraocular penetration of 5-FU. 
These injections are painful and impractical 
for young children and patients with limited 
cooperation.3 Local sponge applications of 
mitomycin-C (MMC) and subconjunctival MMC 
injections with needling have also been used 
to address early bleb failure, but these types 
of application are also cumbersome and lead 
to complications.5-7
The purpose of this study was to compare 
the safety and efficacy of postoperative 
application of topical MMC drops with that of 
subconjunctival 5-FU injections for management 
of early bleb failure. 
METhODS
This randomized comparative study investigated 
the safety and efficacy of topical MMC 
vs. subconjunctival 5-FU for management 
of impending early bleb failure following 
trabeculectomy or combined phacoemulsification 
and trabeculectomy with posterior chamber 
intraocular lens implantation (PT+PCIOL) 
in a consecutive series of patients from June 
2007 to July 2009. The study was approved 
by the ethics committee of the Ophthalmic 
Research Center and was registered at www.
ClinicalTrials.gov (NCT 00644215), according 
to the standards set by the International 
Committee of Medical Journal Editors and the 
World Health Organization. Written informed 
consent was obtained from all patients prior 
to enrollment after providing an explanation 
about the study goals and procedures.
All procedures were performed by three 
surgeons (MP, SY, and AM). A fornix-based 
conjunctival flap was created, and after scleral 
flap dissection, at least five sponges soaked with 
MMC 0.02% were placed under the conjunctiva 
for two minutes for trabeculectomy alone 
and three minutes for phacotrabeculectomy, 
followed by copious irrigation with balanced salt 
solution. After anterior chamber paracentesis, 
the block was removed and a peripheral 
iridectomy was performed. The scleral flap 
was secured with two releasable 10-0 nylon 
sutures and the conjunctiva was repaired with 
10-0 nylon sutures.
Eyes with injected blebs and decreased 
bleb height, with or without increased IOP, 
no later than one month after trabeculectomy 
or combined PT+PCIOL which did not 
respond to frequent topical corticosteroids and 
massage or releasable suture removal, and at 
the same time had a patent internal block on 
gonioscopy, were randomly assigned to the 
study groups according to a computer generated 
randomization scheme. MMC 0.02% drops 
(Kyowa Hakko Kogyo Co., Tokyo, Japan) were 
prepared using artificial tears (Sno tears; Bausch 
& Lomb, London, England) as the vehicle and 
were applied four times a day for two weeks 
and repeated for another two-week period one MMC vs 5-FU for Bleb Failure; Pakravan et al
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week after completion of the initial course if 
signs of failure persisted. To reduce systemic 
absorption of MMC, patients were instructed 
to occlude their puncti by digital compression 
for 5 minutes. Because of ethical obligations, 
5-FU injections were initiated according to 
surgeon’s discretion if signs of failure showed 
an insufficient response to MMC drops at any 
follow up examination. 
The subconjunctival 5-FU group received 5 
milligrams of 5-FU (Ebewe Pharma, Unterach, 
Austria) once daily close to the bleb, until a 
desirable reduction in signs of bleb failure 
appeared or up to a total dose of 65 mg. In eyes 
developing complications, such as filamentary 
keratitis, further injections or MMC drops were 
avoided, however in cases with superficial 
punctate keratitis, the drugs were continued 
with caution.
Recorded data included age, sex, type of 
glaucoma, number and duration of antiglaucoma 
medications, and previous ocular procedures. 
Main outcome measures included IOP and 
bleb morphology according to the Indiana 
Bleb Appearance Grading Scale (IBAGS).8 
Other outcome measures included success rate, 
number of glaucoma medications, best-corrected 
visual acuity (BCVA), and complications. 
Complete success was defined as 5 < IOP ≤ 
18 mmHg without medications and qualified 
success was defined as the same range of IOP 
with one or two topical glaucoma medications. 
For the purpose of bleb grading, slitlamp 
photographs were taken. IBAGS was used 
for morphological classification of filtering 
blebs.8 Based on this grading system, bleb 
height is assessed by the vertical width of the 
conjunctival flap over the scleral surface and 
classified as H0: flat bleb, H1: low elevation, 
H2: moderate elevation, and H3: high elevation. 
Bleb extent represents the dimensions of the 
filtering bleb and is divided into four grades 
including E0: no visible or less than 1 clock 
hour bleb extension, E1: extension equal to or 
greater than 1 clock hour but less than 2 clock 
hours, E2: extension equal to or greater than 2 
clock hours but less than 4 clock hours, and E3: 
extension equal to or greater than 4 clock hours. 
Bleb vascularity is assessed by examination of 
superficial and deep vessels and is divided into 
5 grades including V0: white avascular bleb, 
V1: cystic avascular bleb, V2: mild vascularity, 
V3: moderate vascularity, and V4: extensive 
vascularity. Since only injected blebs without 
leakage (S0) were enrolled in the study, we did 
not employ Seidel test assessment.
Examinations and slitlamp photography 
were performed 1, 7 and 14 days, and 1 and 
3 months after enrollment. Complete eye 
examinations were performed every three 
months thereafter. Data of eyes with at least 
three months of follow up were used for 
statistical analysis; however, failed cases 
during this period were included. Two masked 
glaucoma specialists evaluated the slitlamp 
photographs and classified bleb configuration 
based on IBAGS scores. An independent 
biostatistician was appointed to evaluate the 
outcome measures. Data were modeled using 
the SPSS software package version 15 (SPSS Inc., 
Chicago, IL, USA). Data were compared by t-test, 
Mann-Whitney, Chi-square, and Fisher Exact 
tests. To adjust for baseline effect, analysis of 
covariance (ANCOVA) was utilized. P-values 
less than 0.05 were considered significant. 
RESuLTS 
A total of 37 eyes of 37 patients, including 29 
male (78.5%) and 8 female (21.5%) subjects, 
with mean age of 55.2 ± 23.4 (range, 9 to 85) 
years were included in the study; 19 eyes were 
randomized to receive topical MMC drops 
while 18 eyes underwent 5-FU injections. 
Patients were followed for a mean period of 
11.5 ± 8.0 (median, 8) and 10.9 ± 5.4 (median, 
11) months in the MMC and 5-FU groups, 
respectively (P = 0.589). Table 1 summarizes 
basic and demographic characteristics of 
the patients. No significant difference was 
observed between the study groups in terms 
of age, sex, type of glaucoma, BCVA, mean 
preoperative IOP, cup to disc ratio, duration of 
glaucoma medication use, and previous ocular 
or glaucoma procedures. One difference was 
in the mean number of preoperative glaucoma 
medications which was 2.5 ± 0.7 in the MMC 
group vs. 3.2 ± 0.8 in the 5-FU group (P = 0.012). MMC vs 5-FU for Bleb Failure; Pakravan et al
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Surgical complications were not significantly 
different between the groups (P = 0.605). By 
chance, there were more combined PT+PCIOL 
procedures in the MMC group as compared to 
the 5-FU group [11 (57.9%) vs. 3 (16.7%) eyes, 
P = 0.017]. The mean interval between surgery 
and intervention was 7.9 ± 5.1 and 9.7 ± 5.6 
days in the MMC and 5-FU groups respectively 
(P = 0.345). Thirteen (68.4%) eyes in the MMC 
group received two cycles of therapy, the 
remaining patients received only one cycle of 
MMC drops for two weeks. The mean total 
dose of 5-FU was 19.4 ± 17.0 mg (range, 5 to 
65 mg) administered with a mean number of 
2.8 (range, 1 to 13) injections.
Intraocular pressure was significantly 
reduced from baseline in both study groups at 
1 and 2 weeks and 1, 3, 6, and 12 months (all 
P-values ≤ 0.01). No significant difference was 
observed between the study groups in terms 
of IOP at any interval (all P-values > 0.25) 
(Table 2 and Fig. 1). There were no significant 
differences in bleb height and extent between 
the two groups (bleb extent: P = 0.170, height: 
P = 0.178, vascularity: P = 0.366). In the MMC 
Variable
MMC
(n=19)
5‑Fu
(n=18)
P‑value
Age (years) 61.7 ± 18.9 48.4 ± 25.5 0.082†
Male sex [N(%)] 17 (89.5) 12 (66.7) 0.124‡
Baseline BCVA (LogMAR) 1.18 ± 0.64 0.82 ± 0.64 0.097†
Glaucoma subtype [N(%)] 0.192‡
POAG 5 (26.3) 2 (11.1)
PACG 7 (36.7) 5 (27.8)
Congenital  0 (0) 5 (27.8)
PXF  2 (10.5) 3 (16.7)
Uveitic  2 (10.5) 1 (5.6)
Pseudophakic  3 (15.8) 2 (11.1)
Previous surgeries (N)  1.0 ± 1.2 0.7 ± 1.0 0.443§
Duration of medications 
before surgery (years)
5.6 ± 7.2 6.0 ± 9.8 0.982§
Preoperative  medications (N) 2.5 ± 0.7 3.2 ± 0.8 0.012§
Lens status [N(%)] 0.022*
Phakic  6 (31.6) 13 (72.2)
Pseudophakic  13 (68.4) 5 (27.8)
Preoperative IOP (mmHg) 20.6 ± 8.8 25.8 ± 11.4 0.129†
Cup/disc ratio 87.2 ± 13.6 83.1 ± 17.1 0.424†
Interval between surgery and 
trial (days)
7.9 ± 5.1 9.7 ± 5.6 0.265§
Type of operation [N(%)] 0.017‡
PT+PCIOL 11 (57.9) 3 (16.7)
Trabeculectomy  8 (42.1) 15 (83.3)
Table 1.  Basic and demographic characteristics of 
patients in each study group
† t-test; ‡ Fisher Exact test; § Mann-Whitney test; * chi-square test 
MMC, mitomycin-C; 5-FU, 5-fluorouracil; N, number; BCVA, 
best-corrected visual acuity; POAG, primary open angle 
glaucoma; PACG, primary angle closure glaucoma; PXF, 
pseudoexfoliation; IOP, intraocular pressure; PT+PCIOL, 
combined phacoemulsification and trabeculectomy with 
posterior chamber intraocular lens implantation
Figure 1. Change in intraocular pressure from baseline 
in the MMC and 5-FU groups.
Figure 2. Changes in bleb vascularity from baseline in 
the MMC and 5-FU groups.MMC vs 5-FU for Bleb Failure; Pakravan et al
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group there was a borderline decrease in bleb 
vascularity after one week (P = 0.05), and a 
significant decrease after two weeks, and one 
and three months (P < 0.05 for all comparisons). 
Bleb vascularity was decreased significantly 
in the 5-FU group after one and two weeks, 
and at one and three months (P < 0.05 for all 
comparisons; Fig. 2). The study groups were 
comparable in terms of bleb morphology up to 
3 months after intervention (P = 0.380; Fig. 3).
In the MMC group, complete and qualified 
success was achieved in 13 (68.4%) and 1 (5.3%) 
eyes, respectively; three eyes demonstrated 
failure, two of which had an IOP higher than 
18 mmHg and one eye developed IOP of 
5 mmHg without hypotony maculopathy. In the 
5-FU group, 14 (77.8%) eyes achieved complete 
success and four eyes showed failure due to 
high IOP. There was no significant difference 
in success rates between the study groups 
(P > 0.999; Fisher Exact test, for both success 
rates simultaneously; Fig. 4). Success rates were 
comparable in the study groups throughout 
follow-up as demonstrated by Kaplan-Meier 
analysis (P = 0.974; Fig. 5). The median time 
for survival was 21 months (95% CI: 18-24) in 
the MMC group and 20 months (95% CI: 10-30) 
in the 5-FU group. Six eyes in the MMC group 
received additional 5-FU injections according 
to IOP or bleb appearance at a mean dose of 
10.7 ± 10.1 mg (range, 5 to 65 mg), 35.5 ± 11.8 
days after surgery. Four of these eyes had 
undergone combined PT+PCIOL and two (10.5%) 
demonstrated failure despite 5-FU injections. 
Group
95% CI of Difference P‑value MMC
(n=19)
5‑Fu
(n=18)
Baseline IOP (mean ± SD)  20.6 ± 8.8 25.8 ± 11.4 -12.1 – 1.61 0.129†
First Day (mean ±   SD) 12.4 ± 6.4 11.5 ± 6.0 -3.3 – 5.1 0.671†
Change from baseline -7.3 ± 10.8 -14.4 ± 13.6 -1.4 – 15.4 0.748*
(change %) -27.0 -46.3
P  within group† 0.010 <0.001
First Week (mean ± SD) 10.5 ± 5.3 10.8 ± 8.0 -5.1 – 4.3 0.865†
Change from baseline -9.7 ± 11.0 -16.4 ± 11.9 -1.5 – 15.1 0.939*
(change %) -36.3 -56.7
P  within group† 0.002 <0.001
Second Week (mean ± SD) 12.1 ± 5.0 9.9 ± 6.3 -1.8 – 6.05 0.282†
Change from baseline -8.1 ± 8.6 -15.9 ± 12.1 0.42 – 15.1 0.181*
(change %) -32.4 -56.4
P  within group† 0.001 <0.001
First Month (mean ± SD) 13.3 ± 4.8 11.7 ± 4.3 -1.5 – 4.8 0.301†
Change from baseline -7.6 ± 9.2 -14.1 ± 13.4 -1.5 – 14.3 0.369*
(change %) -26.5 -43.9
P  within group† 0.003 0.001
Third Month (mean ± SD) 12.5 ± 5.0 10.7 ± 4.4 -1.3 – 4.9 0.251†
Change from baseline -8.1 ± 8.9 -15.1 ± 12.3 -0.1 – 14.3 0.196*
(change %) -30.7 -52.0
P  within group† 0.001 <0.001
Sixth Month (mean ± SD) 12.9 ± 5.0 11.2 ± 4.3 -1.5 – 4.8 0.285†
Change from baseline -7.7 ± 8.9 -14.8 ± 12.1 -0.1 – 14.2 0.189*
(change %) -29.0 -50.4
P  within group† 0.001 <0.001
Twelfth Month (mean ± SD) 13.2 ± 6.1 10.6 ± 4.8 -1.1 – 6.3 0.159†
Change from baseline -7.4 ± 10.4 -15.4 ± 12.1 -0.4 – 15.6 0.143*
(change %) -25.4 -52.7
P  within group† 0.006 <0.001
Table 2. Intraocular pressures and changes from baseline in the two groups
† Unadjusted P-value based on t-test; * Adjusted P-value for baseline based on analysis of covariance
MMC, mitomycin-C; 5-FU, 5-fluorouracil; CI, confidence interval; IOP, intraocular pressure; SD, standard deviationMMC vs 5-FU for Bleb Failure; Pakravan et al
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In both groups, the number of glaucoma 
medications decreased significantly. In the 
MMC group it was reduced from 2.5 ± 0.7 
preoperatively, to 0.4 ± 0.7 after 12 months. 
Corresponding figures for the 5-FU group 
were 3.2 ± 0.8 and 0.2 ± 0.4 (P < 0.001 for both 
groups; Fig. 6). Final BCVA was comparable 
between the study groups and was 0.83 ± 0.51 
logarithm of minimum angle of resolution 
(LogMAR) in the MMC and 0.73 ± 0.55 LogMAR 
in the 5-FU group (P = 0.550, ANCOVA). The 
most common complication related to MMC 
was punctate epithelial keratopathy, observed 
in 6 eyes (31.5%), and the most common 
complication of 5-FU injections was filamentary 
keratitis, in 7 eyes (38.9%). Complication rates 
Figure 5. Kaplan-Meier survival curves for cumulative 
success rates in the MMC and 5-FU groups.
Figure 6. Number of medications in each group.
Figure 3. Changes in bleb appearance from baseline in 
the MMC and 5-FU groups.
Figure 4.  Success and failure in the MMC and 5-FU 
groups.MMC vs 5-FU for Bleb Failure; Pakravan et al
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were comparable between the study groups 
(P = 0.140; Table 3).
DISCuSSION
In the present study we compared the safety 
and efficacy of MMC drops with 5-FU injections 
for management of early bleb failure after 
filtering surgery. We found MMC drops to 
be comparable to 5-FU injections in terms of 
IOP, bleb appearance, success rate, number of 
glaucoma medications, visual outcome, and 
overall complications. Complete success was 
similar in both groups and was achieved in 
68.4% and 77.8% of eyes in the MMC and 5-FU 
groups, respectively. 
Adjunctive antimetabolites are used 
postoperatively to reduce subconjunctival 
fibrosis, which is especially important in eyes 
at high risk of failure after trabeculectomy. 
Antimetabolites such as 5-FU and MMC inhibit 
fibroblast proliferation and scar tissue formation.
5-FU is a pyrimidine analog that acts 
by competitive inhibition of the enzyme 
thymidylate synthetase and is cell-cycle specific, 
making it more toxic to replicating cells.9 It 
can be used as a soak during surgery or as 
subconjunctival injections after the procedure. 
Several studies have demonstrated the benefits 
of 5-FU in glaucoma surgery.10-13
MMC is an antibiotic isolated from 
Streptomyces caespitosus and is a hundred 
times more potent than 5-FU and also toxic 
to vascular endothelium. Several studies have 
revealed the efficacy of intraoperative MMC in 
increasing the success rate of trabeculectomy.14,15 
It has been demonstrated that MMC penetrates 
subconjunctival tissues after application over 
an intact conjunctiva.16 Topical MMC drops 
have been used effectively for the treatment 
of corneal intraepithelial neoplasia.17-19 In 
addition, there are limited studies reporting 
that the application of MMC with a sponge 
can improve IOP control after trabeculectomy 
in rabbits and humans.7,8,20 
In a study by Mietz et al7, postoperative 
surface application of MMC was compared 
with intraoperative application. Hypotony was 
more frequent in the group with intraoperative 
application, in which the only case of hypotony 
maculopathy occurred. There was also a 
tendency toward lower IOP in this group. The 
rates of loss of visual acuity exceeding two 
lines and failure were also higher in this group.
Khong and Muecke21 applied topical MMC 
0.04% in 100 eyes of 91 patients with ocular 
surface neoplasia and reported the most common 
complication to be allergic reactions with marked 
pruritus, periocular erythema, and redness in 
34% of cases. Punctal stenosis and epiphora 
developed in 14% of their patients. None of 
these complications were observed in any of 
our patients, which may be due to the lower 
concentration of MMC used in the current study 
(0.02%). Furthermore, we limited MMC drops 
to two cycles of two weeks’ duration with one 
week of discontinuation in between. Of our 
patients, 68.4% were treated with two cycles 
of therapy, the remaining patients received 
only one cycle. Khong and Muecke observed 
no allergic reactions during the first course of 
MMC application in any of their cases; it is 
possible that delayed hypersensitivity could be 
responsible for the reported allergic reactions.21
Araie et al13 used subconjunctival 5-FU in 
263 patients during the first postoperative days 
after trabeculectomy. The mean 5-FU dose was 
36 ± 19.5 mg in eyes with primary open angle 
glaucoma, 49.5 ± 18 mg for refractory glaucoma, 
and 36.5 ± 20 mg for secondary glaucoma. We 
used a mean dose of 19.4 ± 17.0 mg in our 
study. This lower dose is probably due to the 
intraoperative application of MMC in all eyes 
as a routine practice in our study. Araie et al 
reported corneal epithelial defects in 36.8% of 
eyes in their series following 5-FU injections. 
We observed filamentary keratitis in 38.9% 
Complications
Group
P‑value MMC
(n=19)
5‑Fu
(n=18)
Filamentary keratitis 1 (5.3%) 7 (38.9%) 0.016*
Punctate epithelial keratitis 6 (31.5%) 2 (11.1%) 0.232*
Subconjunctival hemorrhage 0 (0.0%) 2 (11.1%) 0.230*
No complication 12 (63.2%) 7 (38.9%) 0.140†
Table 3. Complications of interventions
* Fisher Exact test; † chi-square 
MMC, mitomycin-C; 5-FU, 5-fluorouracilMMC vs 5-FU for Bleb Failure; Pakravan et al
85 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2011; Vol. 6, No. 2
of eyes in the 5-FU group and only 5.26% of 
those receiving MMC. Superficial punctate 
keratopathy was observed in 26.3% of eyes 
receiving MMC drops which responded rapidly 
to lubricants.
In our study, the mean interval between 
initiation of the antimetabolites and surgery was 
8.6 ± 5.2 days in the MMC group vs. 9.9 ± 0.7 
days in the 5-FU group. This is different from 
studies by Van Buskirk12 and Araie et al13, 
in which 5-FU was initiated on the first day 
after surgery. Mietz and Krieglstein5 applied 
topical MMC 0.05 mg/cc for 5 minutes over 
the filtering bleb with a sponge for 3 days 
postoperatively. This approach reduced IOP 
without increasing complications. Reinthal 
et al11 started 5-FU injections 4.6 ± 8.5 days 
postoperatively in 172 eyes of 171 patients 
who had undergone trabeculectomy. The total 
5-FU dose ranged from 5 to 56 mg which was 
similar to our range (5 to 65 mg).
By chance, there were more combined 
PT+PCIOL procedures in the MMC group 
and for this reason eyes in the MMC group 
were at higher risk for bleb failure. Following 
inadequate response to therapy which could 
have been due to a larger number of high-risk 
cases in this group, and according to surgeon’s 
discretion, 5-FU injections were initiated in 
six eyes in the MMC group. Four eyes in 
this group achieved an IOP between 6 and 
18 mmHg without medication, while two eyes 
demonstrated failure despite 5-FU injections. 
We observed complete success rates of 68.4% 
and 77.8% in the MMC and 5-FU groups, 
respectively, which are similar to results of the 
Mietz and Krieglstein5 study, in which 84.6% of 
the patients who received postoperative MMC 
applications with a sponge, achieved complete 
success after 6 months (IOP < 22 mmHg without 
medication).
One of the limitations of our study is the 
duration of follow up, even though 12 months 
seems adequate to compare the response of 
early bleb failure to either treatment protocol. 
The disproportionate distribution of eyes with 
combined surgery into the study groups is 
another limitation of this study.
In this study, we observed comparable safety 
and efficacy for MMC drops in comparison 
with 5-FU injections for management of 
early post-trabeculectomy bleb failure. IOP, 
final bleb morphology, success rates, final 
number of glaucoma medications, and visual 
outcomes were comparable. Moreover, the rate 
of complications was also similar (P = 0.140). 
Postoperative application of MMC drops entails 
advantages such as convenience for both the 
patient and the physician, as compared to 
subconjunctival 5-FU injections. In eyes showing 
signs of early bleb failure following filtering 
surgery and when conservative measures, such 
as frequent topical or systemic corticosteroids, 
ocular massage, and removal of releasable 
sutures or laser suture lysis are not adequate, 
topical MMC 0.02% drops can be initiated 
first, reserving the cumbersome 5-FU injections 
for eyes in which signs of failure show an 
insufficient response to MMC drops.
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